VALSARTAN | N020665 | NOVARTIS PHARMACEUTICALS CORP
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Active | Ohio State University | 90 | 2020-02-25 → 2026-06 | |
| Phase 1 | Not Yet Recruiting | Stony Brook University | 18 | 2026-10-01 → 2028-12-31 | |
| N/A | Not Yet Recruiting | University of Health Sciences Lahore | 102 | 2026-10-01 → 2027-05-31 | |
| Phase 2/3 | Recruiting | Jonathan Beaudoin | 50 | 2026-07-13 → 2029-12-01 | |
| Phase 4 | Recruiting | The Cleveland Clinic | 50 | 2019-11-08 → 2022-12 | |
| Phase 4 | Recruiting | Kyungsub Song | 80 | 2026-05-20 → 2028-12-20 | |
| Phase 4 | Recruiting | Martin Rohacek | 298 | 2026-06-30 → 2028-11-30 | |
| Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2020-08-15 → 2027-05-31 | |
| Phase 2 | Completed | Massachusetts General Hospital | 39 | 2020-09-11 → 2025-07-09 | |
| Phase 3 | Completed | Gruppo di Ricerca GISSI | 1,442 | 2004-11 → 2008-03 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Total Spending
$20.7M
Total Claims
25,913
Beneficiaries
5,891
Avg Cost/Unit
$9.72
Spending Trend
Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.
28 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Feb 7, 2017 | SUPPL -39 | View Letter (PDF) |
| Jul 28, 2015 | SUPPL -38 | View Letter (PDF) |
| Sep 26, 2014 | SUPPL -37 | View Letter (PDF) |
| Mar 19, 2014 | SUPPL -34 | View Letter (PDF) |
| Mar 19, 2014 | SUPPL -35 | View Letter (PDF) |
| Oct 30, 2013 | SUPPL -33 | View Letter (PDF) |
| Aug 14, 2002 | SUPPL -16 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.